Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published September 23, 2008 | Supplemental Material + Published
Journal Article Open

The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila

Abstract

Mutations in PTEN-induced kinase 1 (pink1) or parkin cause autosomal-recessive and some sporadic forms of Parkinson's disease. pink1 acts upstream of parkin in a common genetic pathway to regulate mitochondrial integrity in Drosophila. Mitochondrial morphology is maintained by a dynamic balance between the opposing actions of mitochondrial fusion, controlled by Mitofusin (mfn) and Optic atrophy 1 (opa1), and mitochondrial fission, controlled by drp1. Here, we explore interactions between pink1/parkin and the mitochondrial fusion/fission machinery. Muscle-specific knockdown of the fly homologue of Mfn (Marf) or opa1, or overexpression of drp1, results in significant mitochondrial fragmentation. Mfn-knockdown flies also display altered cristae morphology. Interestingly, knockdown of Mfn or opa1 or overexpression of drp1, rescues the phenotypes of muscle degeneration, cell death, and mitochondrial abnormalities in pink1 or parkin mutants. In the male germline, we also observe genetic interactions between pink1 and the testes-specific mfn homologue fuzzy onion, and between pink1 and drp1. Our data suggest that the pink1/parkin pathway promotes mitochondrial fission and/or inhibits fusion by negatively regulating mfn and opa1 function, and/or positively regulating drp1. However, pink1 and parkin mutant flies show distinct mitochondrial phenotypes from drp1 mutant flies, and flies carrying a heterozygous mutation in drp1 enhance the pink1-null phenotype, resulting in lethality. These results suggest that pink1 and parkin are likely not core components of the drp1-mediated mitochondrial fission machinery. Modification of fusion and fission may represent a novel therapeutic strategy for Parkinson's disease.

Additional Information

© 2008 by The National Academy of Sciences of the USA. Edited by Douglas C. Wallace, University of California Irvine College of Medicine, Irvine, CA, and accepted by the Editorial Board July 30, 2008 (received for review April 25, 2008). This article is a PNAS Direct Submission. Published online before print September 17, 2008, doi: 10.1073/pnas.0803998105. Note. While this article was in review, Yang et al. published a report (Proc Natl Acad Sci USA 105:7070–7075) suggesting that pink1 interacts with drp1, fis1, and opa1, findings that are consistent with this work. We thank G. Mohiddin Lone for generating one construct; Margaret Fuller, Hugo Bellen, and Leo Pallanck for fly stocks; Frank Laski for his microtome; Bruce Hay for comments on the manuscript; and the Guo lab members for discussions. This work was supported by the a National Institute of Health NRSA predoctoral fellowship (to M.W.D.), National Institute of Health Grants K02 and R01 (to M.G.), the Alfred P. Sloan Foundation, American Parkinson's Disease Association, Glenn Family Foundation, and the McKnight Endowment Fund for Neuroscience (to M.G.). Author contributions: H.D., M.W.D., and M.G. designed research; H.D. and M.W.D. performed research; H.D., M.W.D., and M.G. analyzed data; H.H. contributed new reagents/analytic tools; and M.G. wrote the paper. The authors declare no conflict of interest. This article contains supporting information online at www.pnas.org/cgi/content/full/0803998105/DCSupplemental.

Attached Files

Published - DENpnas08.pdf

Supplemental Material - DENpnas08supp.pdf

Files

DENpnas08.pdf
Files (2.7 MB)
Name Size Download all
md5:02d99a648bf5d04ab7c3ca254596e00e
2.0 MB Preview Download
md5:1d26a22e4337fe96274b20b91dd73329
727.4 kB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 17, 2023